A Systematic Review and Mixed Treatment Comparison of the Efficacy of Pharmacological Treatments for Fibromyalgia

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 3, 2011, Pages

  Choy, Ernest ^a   Marshall, David ^b   Gabriel, Zahava L ^c   Mitchell, Stephen A ^d   Gylee, Elizabeth ^d   Dakin, Helen A ^e  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b INVERCLYDE ROYAL HOSPITAL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Decision Resources Group   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Fibromyalgia; Meta analysis; Mixed treatment comparison; Systematic review

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; CITALOPRAM; DULOXETINE; HYPNOTIC SEDATIVE AGENT; IBUPROFEN; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PIRLINDOLE; PLACEBO; PREGABALIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; ARTICLE; BAYES THEOREM; BIBLIOGRAPHIC DATABASE; COCHRANE LIBRARY; DRUG DOSE COMPARISON; DRUG EFFICACY; EMBASE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE SCORE; HUMAN; MEDICAL LITERATURE; MEDICAL OUTCOMES STUDY SLEEP SCALE; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84860389712     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.06.003     Document Type: Article

References (92)

1. White K.P., Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001, 5(4):320-329.
2. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33(2):160-172.
3. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005, 75:6-21.
4. Arnold L.M., Crofford L.J., Mease P.J., Burgess S.M., Palmer S.C., Abetz L., et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008, 73(1):114-120.
5. Hoffman D.L., Dukes E.M. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008, 62(1):115-126.
6. Martin-Sanchez E., Torralba E., Diaz-Dominguez E., Barriga A., Martin J.L. Efficacy of acupuncture for the treatment of fibromyalgia: systematic review and meta-analysis of randomized trials. Open Rheumatol J 2009, 3:25-29.
7. Uceyler N., Hauser W., Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008, 59(9):1279-1298.
8. Hrycaj P., Stratz T., Mennet P., Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome-a preliminary study. J Rheumatol 1996, 23(8):1418-1423.
9. Hench P.K., Cohen R., Mitler M.M. Fibromyalgia: effects of temazepam, amitriptyline and placebo on pain and sleep. Sleep Res 1989, 18:335.
10. Quimby L.G., Gratwick G.M., Whitney C.D., Block S.R. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 1989, 19:140-143.
11. Staud R., Spaeth M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr 2008, 13(3 Suppl 5):12-17.
12. Hauser W., Bernardy K., Uceyler N., Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin-A meta-analysis of randomized controlled trials. Pain 2009, 145(1-2):69-81.
13. Nishishinya B., Urrutia G., Walitt B., Rodriguez A., Bonfill X., Alegre C., et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford) 2008, 47(12):1741-1746.
14. Hauser W., Petzke F., Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010, 11(6):505-521.
15. Tzellos T.G., Toulis K.A., Goulis D.G., Papazisis G., Zampeli V.A., Vakfari A., et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 2010, 35(6):639-656.
16. Hauser W., Petzke F., Uceyler N., Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011, 50(3):532-543.
17. Carville S.F., Arendt-Nielsen S., Bliddal H., Blotman F., Branco J.C., Buskila D., et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008, 67(4):536-541.
18. Goldenberg D.L., Burckhardt C., Crofford L. Management of fibromyalgia syndrome. JAMA 2004, 292(19):2388-2395.
19. Eich W., Hauser W., Friedel E., Klement A., Herrmann M., Petzke F., et al. [Definition, classification and diagnosis of fibromyalgia syndrome]. Z Rheumatol 2008, 67(8):665-666. 668-72, 674-6.
20. Mease P.J., Clauw D.J., Gendreau R.M., Rao S.G., Kranzler J., Chen W., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009, 36(2):398-409.
21. Mease P.J., Russell I.J., Arnold L.M., Florian H., Young J.P., Martin S.A., et al. A randomized double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008, 35(3):502-514.
22. Chappell A.S., Littlejohn G., Kajdasz D., D'Souza D.N., Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Abstract no. THU 0370 2008, European League Against Rheumatism, Paris.
23. Sim J., Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain 2002, 18(5):324-336.
24. Baker K., Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep 2005, 9(5):301-306.
25. Crofford L.J., Appleton B.E. The treatment of fibromyalgia: a review of clinical trials. Curr Rheumatol Rep 2000, 2(2):101-103.
26. Rossy L.A., Buckelew S.P., Dorr N., Hagglund K.J., Thayer J.F., McIntosh M.J., et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 1999, 21(2):180-191.
27. Carville S.F., Choy E.H. Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. J Rheumatol 2008, 35(11):2094-2105.
28. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23(20):3105-3124.
29. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331(7521):897-900.
30. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
31. Tugwell P., Boers M., Brooks P., Simon L., Strand V., Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007, 8:38.
32. Jansen J.P., Crawford B., Bergman G., Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008, 11(5):956-964.
33. Ades A.E., Sculpher M., Sutton A., Abrams K., Cooper N., Welton N., et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006, 24(1):1-19.
34. Guide to the Methods of Technology Appraisal June 2008 National Institute of Clinical Excellence. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
35. WinBUGS with DoodleBUGS version 1.4. Cambridge/London, UK; 2003-07 [updated 2003-07; cited] Bayesian inference using Gibbs Sampling (BUGS). http://www.mrc-bsu.cam.ac.uk/bugs.
36. Bristol University, Department of Community Based Medicine Mixed Treatment Comparisons. https://www.bris.ac.uk/cobm/research/mpes/mtc.html.
37. Cooper N.J., Sutton A.J., Lu G., Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006, 166(12):1269-1275.
38. Salanti G., Higgins J.P., Ades A.E., Ioannidis J.P. Evaluation of networks of randomized trials. Stat Methods Med Res 2008, 17(3):279-301.
39. Ginsberg F., Joos E., Geczy J. A pilot randomised placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskeletal Pain 1998, 6:5-17.
40. Patkar A.A., Masand P.S., Krulewicz S., Mannelli P., Peindl K., Beebe K.L., et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 2007, 120(5):448-454.
41. Giordano N., Geraci S., Santacroce C., Mattii G., Battisti E., Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. Curr Therapeut Res Clin Exp 1999, 60(12):696-702.
42. Anderberg U.M., Marteinsdottir I., von Knorring L. Citalopram in patients with fibromyalgia-a randomized, double-blind, placebo-controlled study. Eur J Pain 2000, 4(1):27-35.
43. Norregaard J., Volkmann H., Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995, 61(3):445-449.
44. Russell I.J., Mease P.J., Smith T.R., Kajdasz D.K., Wohlreich M.M., Detke M.J., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136(3):432-444.
45. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50(9):2974-2984.
46. Arnold L.M., Rosen A., Pritchett Y.L., D'Souza D.N., Goldstein D.J., Iyengar S., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119(1-3):5-15.
47. Gendreau R.M., Thorn M.D., Gendreau J.F., Kranzler J.D., Ribeiro S., Gracely R.H., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005, 32(10):1975-1985.
48. Clauw D.J., Mease P., Palmer R.H., Gendreau R.M., Wang Y. Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008, 30(11):1988-2004.
49. Russell J., Kamin M., Bennett R.M., Schnitzer T.J., Green J.A., Katz W.A. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000, 6:250-257.
50. Arnold L.M., Russell I.J., Diri E.W., Duan W.R., Young J.P., Sharma U., et al. A 14-week randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008, 9(9):792-805.
51. Crofford L.J., Mease P.J., Simpson S.L., Young J.P., Martin S.A., Haig G.M., et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008, 136(3):419-431.
52. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52(4):1264-1273.
53. Pauer L., Danneskiold Samsøe B., Jespersen A., Atkinson G., Whelan L., Leon T. Pregabalin for management of fibromyalgia (FM): a 14-week randomized, double-blind, placebo-controlled, monotherapy trial (Study A0081100). Abstract no. THU 0382 2008, European League Against Rheumatism, Paris.
54. Heymann R.E., Helfenstein M., Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 2001, 19(6):697-702.
55. Ginsberg F., Mancaux A., Joos E., Vanhove P., Famaey J.P. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain 1996, 4(3):37-47.
56. Russell I.J., Fletcher E.M., Michalek J.E., McBroom P.C., Hester G.G. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 1991, 34(5):552-560.
57. Quijada Carrera J., Valenzuela Castaño A., Povedano Gómez J., Fernández Rodriguez A., Hernánz Mediano W., Gutierrez Rubio A., et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 1996, 65(2-3):221-225.
58. Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50(6):683-691.
59. Ades A.E. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med 2005, 22(19):2995-3016.
60. O'Regan C., Ghement I., Eyawo O., Guyatt G.H., Mills E.J. Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. Trials 2009, 10:86.
61. Giesecke T., Williams D.A., Harris R.E., Cupps T.R., Tian X., Tian T.X., et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003, 48(10):2916-2922.
62. Holman A.J., Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005, 52(8):2495-2505.
63. Moldofsky H., Alvarez-Horine S. Effects of sodium oxybate on sleep physiology and sleep-related symptoms in fibromyalgia. Abstract no. THU 0381 2008, European League Against Rheumatism, Paris.
64. Scharf M.B., Baumann M., Berkowitz D.V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003, 30(5):1070-1074.
65. Arnold L.M., Hess E.V., Hudson J.I., Welge J.A., Berno S.E., Keck P.E. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112(3):191-197.
66. Branco J.C., Perrot S., Bragee G., Zachrisson O., Mikkelsen K., Mainguy Y. Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, randomized, double-blind, placebo-controlled trial. Abstract no. THU 0365 2008, European League Against Rheumatism, Paris.
67. Gracely R.H., Jensen K., Petzke F., Marcus H., Carville S., Choy E. The effect of milnacipran on pain modulatory systems in fibromyalgia: an FMRI analysis. Abstract no. THU 0378 2008, European League Against Rheumatism, Paris.
68. Chappell A.S., Littlejohn G., Kajdasz D.K., Scheinberg M., D'Souza D.N., Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 2009, 25(5):365-375.
69. Erhan E., Yegul I., Pirim A., Veznedaroglu B. A double-blind trial comparing mirtazapine with placebo in the treatment of fibromyalgia patients with major depressive disorder (621-P227) 2005, International Association for the Study of Pain 11th World Congress on Pain, Sydney, Australia.
70. Borman P., Keskin D., Bodur H. The efficacy of venlafaxine in treatment of fibromyalgia 2004, European League against Rheumatism, Berlin.
71. Clauw D.J., Palmer R.H., Thacker K., Gendreau M., Mease P. Milnacipran efficacy in the treatment of fibromyalgia syndrome: a 15-week, randomised, double-blind, placebo-controlled trial 2007, ACR/ARHP, Boston (MA).
72. Goldenberg D., Clauw D.J., Palmer R.H., Mease P., Gendreau R.M. One-year durability of response to milnacipran treatment for fibromyalgia 2007, ACR/ARHP, Boston (MA).
73. Clauw D.J., Palmer R.H., Vitton O., Mease P., Gendreau R.M. The efficacy and safety of milnacipran in the treatment of fibromyalgia 2007, ACR/ARHP, Boston (MA).
74. Chappell A., Bradley L., Wiltse C., D'Souza D.N., Spaeth M. Duloxetine 60-120 mg versus placebo in the treatment of fibromyalgia syndrome 2007, ACR/ARHP, Boston (MA).
75. Chappell A.S., Bradley L.A., Wiltse C., Detke M.J., D'Souza D.N., Spaeth M. A six-month, double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008, 1:91-102.
76. Vitton O., Gendreau M., Gendreau J., Kranzler J., Rao S.G. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacol 2004, 19(Suppl 1):S27-S35.
77. Gur A., Calgan N., Nas K., Cevik R., Sarac A.J. Low dose of tramadol in the treatment of fibromyalgia syndrome: a controlled clinical trial versus placebo 2006, European League against Rheumatism, Amsterdam.
78. Bennett R.M., Kamin M., Karim R., Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003, 114(7):537-545.
79. Bennett R.M., Schein J., Kosinski M.R., Hewitt D.J., Jordan D.M., Rosenthal N.R. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005, 53(4):519-527.
80. Rowbotham M.C., Baruth T., Meadoff T., Lecomte M.D., Levi M., Petersen K.L. A randomized, double-blind, placebo-controlled trial of levetiracetam for treatment of pain and disturbed sleep associated with fibromyalgia 2007, 4th World Congress World Institute of Pain, Budapest, Hungary.
81. Duan R., Diri E., Young J.P., Martin S., Haig G., Barrett J. Efficacy of pregablin monotherapy for relief of pain associated with fibromyalgia: time course and durability of pain results of a 14-week, double-blind, placebo-controlled trial 2007, ACR/ARHP, Boston (MA).
82. Simpson S., Young J.P., Haig G., Barrett J. Pregabalin therapy for durability of meaningful relief of fibromyalgia 2007, ACR/ARHP, Boston (MA).
83. Arnold L.M., Goldenberg D.L., Stanford S.B., Lalonde J.K., Sandhu H.S., Keck P.E., et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007, 56(4):1336-1344.
84. Skrabek R.Q., Galimova L., Ethans K., Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008, 9(2):164-173.
85. Capaci K., Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clin 2002, 14(3):223-238.
86. Ataoglu S., Ataoglu A., Erdogan F., Sarac J. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci 1997, 27:535-539.
87. Nicolodi M., Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol 1996, 398:373-379.
88. Hannonen P., Malminiemi K., Yli Kerttula U., Isomeri R., Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998, 37(12):1279-1286.
89. Ozgocmen S., Ozyurt H., Sogut S., Akyol O., Ardicoglu O., Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2006, 26(7):598-603.
90. Nishikai M., Akiya K. Fluvoxamine therapy for fibromyalgia. J Rheumatol 2003, 30(5):1124.
91. Goldenberg D., Mayskiy M., Mossey C., Ruthazer R., Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39(11):1852-1859.
92. Carette S., Bell M.J., Reynolds W.J., Haraoui B., McCain G.A., Bykerk V.P., et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial. Arthritis Rheum 1994, 37(1):32-40.